World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 February 2015
Main ID:  NCT00984932
Date of registration: 24/09/2009
Prospective Registration: No
Primary sponsor: Faculty of Medicine, University of Alexandria
Public title: Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension
Scientific title: The Effect of Rosuvastatin on Vascular Dysfunction and Inflammatory Markers in Systemic Sclerosis-related Pulmonary Hypertension: Randomized, Double-Blind Placebo-Controlled Trial
Date of first enrolment: September 2008
Target sample size: 40
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT00984932
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment  
Phase:  Phase 3
Countries of recruitment
Egypt
Contacts
Name:     Anna Abou-Raya
Address: 
Telephone:
Email:
Affiliation:  University of Alexandria
Key inclusion & exclusion criteria

Inclusion Criteria:

- New York Heart Association (NYHA) class III

- A mean pulmonary artery pressure (mPAP) of > 30mmHg at rest

Exclusion Criteria:

- Smoking

- Diabetes mellitus

- Hypercholesterolemia

- Hypertension

- Cardiac insufficiency

- Coexisting hepatic and renal diseases

- Use of drugs known to interact with statins.

- Patients with severe interstitial lung fibrosis



Age minimum: N/A
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Systemic Sclerosis
Intervention(s)
Drug: Rosuvastatin
Primary Outcome(s)
exercise capacity measured by the SMWT, mPAP and WHO functional class change [Time Frame: At baseline and After 6 months of therapy]
Secondary Outcome(s)
Secondary ID(s)
alexmed116613963
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history